Long-term Follow-up of HALT-C Sustained Virologic Responders

Investigators:

Principal Investigator: Karen Lindsay

Co-Investigators: Marc Ghany, Anna Lok, Timothy Morgan

Hypotheses/Aims

All 180 patients who developed a virological response at week 20 of the HALT-C Study, completed 48 weeks of peginterferon with ribavirin therapy, and continued to have undetectable serum HCV RNA at week 72, twenty four weeks after completing treatment are eligible for this Ancillary Study. These Sustained Virologic Responder (SVR) subjects completed treatment in 2004, and the last patient completed their week 72 visit in 2004. Patients will be asked to complete one study visit either in-person or by telephone. There will be no study treatment/drug. This study will assess the frequency of clinical outcomes (variceal bleeding, ascites, CTP scores > 7, liver transplant, death) and hepatocellular carcinoma (HCC) and factors associated with these outcomes.